These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 37648114)
1. New insights into the binding of PF4 to long heparin oligosaccharides in ultralarge complexes using mass spectrometry. Shi D; Zhao H; Bu C; Fraser K; Wang H; Dordick JS; Linhardt RJ; Zhang F; Shi F; Chi L J Thromb Haemost; 2023 Dec; 21(12):3608-3618. PubMed ID: 37648114 [TBL] [Abstract][Full Text] [Related]
6. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Warkentin TE; Cook RJ; Marder VJ; Sheppard JA; Moore JC; Eriksson BI; Greinacher A; Kelton JG Blood; 2005 Dec; 106(12):3791-6. PubMed ID: 16109780 [TBL] [Abstract][Full Text] [Related]
7. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Greinacher A; Gopinadhan M; Günther JU; Omer-Adam MA; Strobel U; Warkentin TE; Papastavrou G; Weitschies W; Helm CA Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2386-93. PubMed ID: 16873726 [TBL] [Abstract][Full Text] [Related]
8. Development of a method to analyze the complexes of enoxaparin and platelet factor 4 with size-exclusion chromatography. Wu F; Dong K; Zhu M; Zhang Q; Xie B; Li D; Gan H; Linhardt RJ; Zhang Z J Pharm Biomed Anal; 2019 Feb; 164():668-671. PubMed ID: 30472585 [TBL] [Abstract][Full Text] [Related]
9. Characterization of complexes of PF4 and heparins by size-exclusion chromatography coupled with multi-angle light scattering detector. Zhao J; Xue Y; Tian H; Qiu P; Ouyang Y; Liu H; Yi L; Zhang Z J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Feb; 1233():124004. PubMed ID: 38199058 [TBL] [Abstract][Full Text] [Related]
10. Characterization of the interaction between platelet factor 4 and homogeneous synthetic low molecular weight heparins. Nguyen TH; Xu Y; Brandt S; Mandelkow M; Raschke R; Strobel U; Delcea M; Zhou W; Liu J; Greinacher A J Thromb Haemost; 2020 Feb; 18(2):390-398. PubMed ID: 31573759 [TBL] [Abstract][Full Text] [Related]
11. Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. Warkentin TE; Cook RJ; Marder VJ; Greinacher A J Thromb Haemost; 2010 Mar; 8(3):504-12. PubMed ID: 20050998 [TBL] [Abstract][Full Text] [Related]
12. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Amiral J; Bridey F; Wolf M; Boyer-Neumann C; Fressinaud E; Vissac AM; Peynaud-Debayle E; Dreyfus M; Meyer D Thromb Haemost; 1995 Jan; 73(1):21-8. PubMed ID: 7740492 [TBL] [Abstract][Full Text] [Related]
13. Characterization of PF4-Heparin Complexes by Photon Correlation Spectroscopy and Zeta Potential. Bertini S; Fareed J; Madaschi L; Risi G; Torri G; Naggi A Clin Appl Thromb Hemost; 2017 Oct; 23(7):725-734. PubMed ID: 28118750 [TBL] [Abstract][Full Text] [Related]
14. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226 [TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia. Walenga JM; Prechel M; Jeske WP; Hoppensteadt D; Maddineni J; Iqbal O; Messmore HL; Bakhos M Br J Haematol; 2008 Oct; 143(1):92-9. PubMed ID: 18671707 [TBL] [Abstract][Full Text] [Related]
16. Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin-induced thrombocytopenia. Nazy I; Clare R; Staibano P; Warkentin TE; Larché M; Moore JC; Smith JW; Whitlock RP; Kelton JG; Arnold DM J Thromb Haemost; 2018 Jul; 16(7):1402-1412. PubMed ID: 29723924 [TBL] [Abstract][Full Text] [Related]
17. Heparin-induced thrombocytopenia--therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. Krauel K; Fürll B; Warkentin TE; Weitschies W; Kohlmann T; Sheppard JI; Greinacher A J Thromb Haemost; 2008 Dec; 6(12):2160-7. PubMed ID: 18983520 [TBL] [Abstract][Full Text] [Related]
18. Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia. Horne MK; Hutchison KJ Am J Hematol; 1998 May; 58(1):24-30. PubMed ID: 9590145 [TBL] [Abstract][Full Text] [Related]
19. Modulation of ultralarge immune complexes in heparin-induced thrombocytopenia. Cai Z; Bdeir K; Yarovoi SV; Rauova L; Arepally GM; Khandelwal S; Rollin J; Gruel Y; Zaitsev S; Poncz M; Greene MI; Cines DB J Thromb Haemost; 2023 Mar; 21(3):652-666. PubMed ID: 36696211 [TBL] [Abstract][Full Text] [Related]
20. Atomic features of an autoantigen in heparin-induced thrombocytopenia (HIT). Cai Z; Zhu Z; Greene MI; Cines DB Autoimmun Rev; 2016 Jul; 15(7):752-5. PubMed ID: 26970483 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]